Journal
NEURO-ONCOLOGY
Volume 16, Issue 6, Pages 848-855Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/not241
Keywords
audiology; brain neoplasms; late effects; ototoxicity; platinum drugs
Categories
Funding
- National Cancer Institute Cancer Center CORE [CA 21765]
- Noyes Brain Tumor Foundation
- Musicians Against Childhood Cancer (MACC)
- America Lebanese Syrian Associated Charities (ALSAC)
Ask authors/readers for more resources
The purpose of this study was to evaluate amifostine for protection from cisplatin-induced serious hearing loss in patients with average-risk medulloblastoma by extending a previous analysis to a much larger sample size. In addition, this study aimed to assess amifostine with serious hearing loss in patients with high-risk medulloblastoma treated with cisplatin. Newly diagnosed medulloblastoma patients (n = 379; ages 3-21 years), enrolled on one of 2 sequential St. Jude clinical protocols that included 4 courses of 75 mg/m(2) cisplatin, were compared for hearing loss by whether or not they received 600 mg/m(2) of amifostine immediately before and 3 hours into each cisplatin infusion. Amifostine administration was not randomized. The last audiological evaluation between 5.5 and 24.5 months following protocol treatment initiation was graded using the Chang Ototoxicity Scale. A grade of a parts per thousand yen2b (loss requiring a hearing aid or deafness) was considered a serious event. Among average-risk patients (n = 263), amifostine was associated with protection from serious hearing loss (adjusted OR, 0.30; 95% CI, 0.14-0.64). For high-risk patients (n = 116), however, there was not sufficient evidence to conclude that amifostine prevented serious hearing loss (OR, 0.89; 95% CI, 0.31-2.54). Although patients in this study were not randomly assigned to amifostine treatment, we found evidence in favor of amifostine administration for protection against cisplatin-induced serious hearing loss in average-risk but not in high-risk, medulloblastoma patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available